Company news
Percheron Therapeutics Limited news in 2022
Percheron Therapeutics Limited's news releases, calls and decks from 2022, newest first.
Antisense Therapeutics CEO announces retirement
November 14, 2022
ATL1102 tox study to support clinical program in the US
November 13, 2022
Dosing commenced in DMD combination therapy study
September 11, 2022
ATL1102 Revised Clinical Development Plans Presentation
September 6, 2022
ATL1102 Revised Plans accelerate reporting of unblinded data
September 6, 2022
Appendix 4E and Full Year Statutory Accounts
August 31, 2022
Long COVID study identifies diagnostic & therapeutic targets
August 19, 2022
Reinstatement to Official Quotation
August 19, 2022
Long Covid-19 Collaboration Outcomes Presentation
August 19, 2022
Voluntary Suspension
August 17, 2022
ATL1102 DMD Clinical Trial Application Submitted in Europe
July 12, 2022
New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
June 19, 2022
Prospectus
April 11, 2022
Bonus Option Offer
April 11, 2022
Long COVID-19 strategic collaboration with US Experts
February 24, 2022
Dosing commenced in MCRI collaboration animal study
February 7, 2022
Quarterly Report and Appendix 4C
January 26, 2022
Decks in 2022
- Technical Presentation (September 2022)
Technical · 6 slides · Sep 7, 2022
- Technical Presentation (August 2022)
Technical · 28 slides · Aug 19, 2022